Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience

References

• Walker-Bone K, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BMJ 2000;321:936–40
   Google Scholar
• Sack KE. Osteoarthritis. A continuing challenge. West J Med 1995;163:579–86
   PubMedGoogle Scholar
• Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005;35:1–10
   PubMed Web of Science ®Google Scholar
• Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019–27
   PubMed Web of Science ®Google Scholar
• Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776–83
   Google Scholar
• Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370–7
   PubMed Web of Science ®Google Scholar
• Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021–9
   PubMed Web of Science ®Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081–91
   PubMed Web of Science ®Google Scholar
• Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61:1351–78
   Google Scholar
• Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004;5:1347–57
   PubMed Web of Science ®Google Scholar
• Gonzalez E, de la Cruz C, de Nicolas R, et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994;41:171–8
   PubMedGoogle Scholar
• Yamazaki R, Kawai S, Matsuzaki T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181–7
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999;289:676–81
   PubMed Web of Science ®Google Scholar
• Hinz B, Brune K. Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol 2004;16:628–33
   PubMed Web of Science ®Google Scholar
• Diaz C, Rodriguez de la Serna A, Geli C, et al. Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis: a multicentre study. Eur J Rheumatol Inflamm 1996;16:17–22
   Google Scholar
• Kornasoff D, Frerick H, Bowdler J, et al. Aceclofenac is a well tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 1997;16:32–8
   PubMed Web of Science ®Google Scholar
• Perez Busquier M, Calero E, Rodriguez M, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 1997;16:154–9
   PubMed Web of Science ®Google Scholar
• Preservex tablets. In: Walker G (Ed). ABPI compendium of data sheets and summaries of product characteristics 1999–2000. London: Datapharm Publications Ltd, 1999:1680–1
   Google Scholar
• Torri G, Vignati C, Agrifoglio E, et al. Aceclofenac versus piroxicam in the management of osteoarthritis of the knee: a double-blind controlled study. Curr Ther Res 1994;55:576–83
   Web of Science ®Google Scholar
• Ward DE, Veys EM, Bowdler JM, et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14:656–62
   PubMed Web of Science ®Google Scholar
• Maneiro E, Lopez-Armada MJ, Fernandez-Sueiro JL, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol 2001;28:2692–9
   PubMed Web of Science ®Google Scholar
• Akimoto H, Yamazaki R, Hashimoto S, et al. 4´-Hydroxyaceclofenac suppresses the interleukin-1 induced production of promatrix metalloproteinases and release of sulfatedglycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 2000;401:429–36
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4´-hydroxyaceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and prostromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000;49:133–8
   PubMed Web of Science ®Google Scholar
• Spiegel BM, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795–806
   PubMed Web of Science ®Google Scholar
• Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003;79(933):377–83
   PubMedGoogle Scholar